Loading clinical trials...
Loading clinical trials...
Previous studies have shown that there is a large inter-individual variability in the degree of bone loss during glucocorticoid treatment, and while some patients experience extensive bone loss other patients\' bone mass remains stable. The aim of the study is to find a biomarker that can be used to identify individuals at risk of glucocorticoid-induced bone loss. The study will include 36 healthy volunteers, that will be randomized to receive either glucocorticoid treatment or placebo. During the study blood samples, bone marrow samples, bone tissue samples, and adipose tissue samples are taken and an oral glucose tolerance test is performed.
Age
18 - 50 years
Sex
ALL
Healthy Volunteers
Yes
Hospital of South West Jutland
Esbjerg, Denmark
Odense University Hospital
Odense C, Denmark
Start Date
November 4, 2024
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
December 2, 2024
36
ESTIMATED participants
Prednisolone
DRUG
Placebo
DRUG
Lead Sponsor
Odense University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions